Basic Information
| RNALocate ID: | RLID:11003983 |
| RNA Symbol: | hsa-miR-500a-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-500a-5p |
| RNA ID: | miRBase:MIMAT0004773 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002664 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002665 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11003982 | Exosome | Primary dendritic cells | 21505438 |
| RLID:11003984 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000685 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001555 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-500a-5p | Medulloblastoma | MNDR-E-MI-55312 |
| MNDR | hsa-miR-500a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-55313 |
| MNDR | hsa-miR-500a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-55314 |
| MNDR | hsa-miR-500a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-55315 |
| MNDR | hsa-miR-500a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-55316 |
| MNDR | hsa-miR-500a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-55317 |
| MNDR | hsa-miR-500a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-55318 |
| MNDR | hsa-miR-500a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-55319 |
| MNDR | hsa-miR-500a-5p | Lupus nephritis | MNDR-E-MI-55320 |
| MNDR | hsa-miR-500a-5p | Prostate cancer | MNDR-E-MI-55321 |
| MNDR | hsa-miR-500a-5p | Gastric cancer | MNDR-E-MI-55322 |
| MNDR | hsa-miR-500a-5p | Alzheimer disease | MNDR-E-MI-55323 |
| MNDR | hsa-miR-500a-5p | Dysautonomia familial | MNDR-E-MI-55324 |
| MNDR | hsa-miR-500a-5p | Seizures | MNDR-E-MI-55325 |
| MNDR | hsa-miR-500a-5p | Leukemia | MNDR-E-MI-55326 |
| MNDR | hsa-miR-500a-5p | Friedreich ataxia | MNDR-E-MI-55327 |
| MNDR | hsa-miR-500a-5p | Lung cancer | MNDR-E-MI-55328 |
| MNDR | hsa-miR-500a-5p | Down syndrome | MNDR-E-MI-55329 |
| MNDR | hsa-miR-500a-5p | Parkinson disease | MNDR-E-MI-55330 |
| MNDR | hsa-miR-500a-5p | Breast cancer | MNDR-E-MI-55331 |
| MNDR | hsa-miR-500a-5p | Pancreatic cancer | MNDR-E-MI-55332 |
| MNDR | hsa-miR-500a-5p | Melanoma | MNDR-E-MI-55333 |
| MNDR | hsa-miR-500a-5p | Nephroblastoma | MNDR-E-MI-55334 |
| MNDR | hsa-miR-500a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-55335 |
| MNDR | hsa-miR-500a-5p | Familial ovarian cancer | MNDR-E-MI-55336 |
| MNDR | hsa-miR-500a-5p | Prostate adenocarcinoma | MNDR-E-MI-55337 |
| MNDR | hsa-miR-500a-5p | Carcinoma ductal breast | MNDR-E-MI-55338 |
| MNDR | hsa-miR-500a-5p | Glioblastoma | MNDR-E-MI-55339 |
| MNDR | hsa-miR-500a-5p | Glioma | MNDR-E-MI-55340 |
| MNDR | hsa-miR-500a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-55341 |
| MNDR | hsa-miR-500a-5p | Liposarcoma | MNDR-E-MI-55342 |
| MNDR | hsa-miR-500a-5p | Gastric adenocarcinoma | MNDR-E-MI-55343 |
| MNDR | hsa-miR-500a-5p | Lung squamous cell carcinoma | MNDR-E-MI-55344 |
| MNDR | hsa-miR-500a-5p | Lung adenocarcinoma | MNDR-E-MI-55345 |
| MNDR | hsa-miR-500a-5p | Adrenocortical carcinoma | MNDR-E-MI-55346 |
| MNDR | hsa-miR-500a-5p | Ovarian carcinoma | MNDR-E-MI-55347 |
| MNDR | hsa-miR-500a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-55348 |
| MNDR | hsa-miR-500a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-55349 |
| MNDR | hsa-miR-500a-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-55350 |
| MNDR | hsa-miR-500a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-55351 |
| MNDR | hsa-miR-500a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-55352 |
| MNDR | hsa-miR-500a-5p | Cholangiocarcinoma | MNDR-E-MI-55353 |
| MNDR | hsa-miR-500a-5p | Stomach carcinoma | MNDR-E-MI-55354 |
| MNDR | hsa-miR-500a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-55355 |
| MNDR | hsa-miR-500a-5p | Acute t cell leukemia | MNDR-E-MI-55356 |
| MNDR | hsa-miR-500a-5p | Breast invasive carcinoma | MNDR-E-MI-55357 |
| MNDR | hsa-miR-500a-5p | Hepatocellular carcinoma | MNDR-E-MI-55358 |
| MNDR | hsa-miR-500a-5p | Familiar ovarian carcinoma | MNDR-E-MI-55359 |
| MNDR | hsa-miR-500a-5p | Retinoblastoma | MNDR-E-MI-55360 |
| MNDR | hsa-miR-500a-5p | Tonsil cancer | MNDR-E-MI-55361 |
| MNDR | hsa-miR-500a-5p | Neuromyelitis optica | MNDR-E-MI-55362 |
| MNDR | hsa-miR-500a-5p | Colorectal cancer | MNDR-E-MI-55363 |
| MNDR | hsa-miR-500a-5p | Nasopharynx carcinoma | MNDR-E-MI-55364 |
| MNDR | hsa-miR-500a-5p | Multiple myeloma | MNDR-E-MI-55365 |
| MNDR | hsa-miR-500a-5p | Nasopharyngeal cancer | MNDR-E-MI-55366 |
| MNDR | hsa-miR-500a-5p | Gait ataxia | MNDR-E-MI-55367 |
| MNDR | hsa-miR-500a-5p | Stroke lacunar | MNDR-E-MI-55368 |
| MNDR | hsa-miR-500a-5p | Breast cancer her3+ negative | MNDR-E-MI-55369 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CYLD | Homo sapiens | RR00385277 |
TOP